CCL2 and neoplasm: Secondly, we performed a pilot study using TNC+ tumors with a neutralizing anti-CCL2 antibody, where we injected i.p. at 5 mg/kg and 10 mg/kg (five injections) based on published studies using anti-CCL2 antibodies [68,69,70,71] or i.t. at 1 mg/kg (three injections), which gave a good antibody exposure in this tumor model in our group in the past [25].